Cargando…

Therapeutic implications of PD-L1 expression in bladder cancer with squamous differentiation

BACKGROUND: Immune checkpoint inhibitors (ICI) are an integral part of bladder cancer therapy, however, the relevance of ICI treatment for mixed and pure squamous cell carcinoma of the bladder remains poorly studied. Therefore, we analysed the expression of programmed death-ligand 1 (PD-L1) in uroth...

Descripción completa

Detalles Bibliográficos
Autores principales:	Morsch, Ronja, Rose, Michael, Maurer, Angela, Cassataro, Maria Angela, Braunschweig, Till, Knüchel, Ruth, Vögeli, Thomas-Alexander, Ecke, Thorsten, Eckstein, Markus, Weyerer, Veronika, Esposito, Irene, Ackermann, Maximilian, Niegisch, Günter, Gaisa, Nadine T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7079494/ https://www.ncbi.nlm.nih.gov/pubmed/32188412 http://dx.doi.org/10.1186/s12885-020-06727-2

Ejemplares similares

Evaluation of Therapeutic Targets in Histological Subtypes of Bladder Cancer
por: Wucherpfennig, Sophie, et al.
Publicado: (2021)

SWI/SNF Alterations in Squamous Bladder Cancers
por: Achenbach, Fabian, et al.
Publicado: (2020)

ARID1A-deficiency in urothelial bladder cancer: No predictive biomarker for EZH2-inhibitor treatment response?
por: Garczyk, Stefan, et al.
Publicado: (2018)

EGFR activity addiction facilitates anti-ERBB based combination treatment of squamous bladder cancer
por: Rose, Michael, et al.
Publicado: (2020)

Epigenetic inactivation of ST6GAL1 in human bladder cancer
por: Antony, Pia, et al.
Publicado: (2014)

Analysis of CXCL9, PD1 and PD-L1 mRNA in Stage T1 Non-Muscle Invasive Bladder Cancer and Their Association with Prognosis
por: Kubon, Jennifer, et al.
Publicado: (2020)

Comparative genomic profiling of glandular bladder tumours
por: Maurer, Angela, et al.
Publicado: (2020)

Effective Radiosensitization of Bladder Cancer Cells by Pharmacological Inhibition of DNA-PK and ATR
por: Chughtai, Ahmed Ali, et al.
Publicado: (2022)

Progression of urothelial carcinoma in situ of the urinary bladder: a switch from luminal to basal phenotype and related therapeutic implications
por: Barth, Isabella, et al.
Publicado: (2018)

Editorial for: Bertoni et al. ex vivo fluorescence confocal microscopy: prostatic and periprostatic tissues atlas and evaluation of the learning curve
por: Braunschweig, Till, et al.
Publicado: (2020)

Does robotic radical cystectomy impede oncological outcome in bladder cancer patients?
por: Niegisch, Günter
Publicado: (2018)

Characterisation of tumour-immune phenotypes and PD-L1 positivity in squamous bladder cancer
por: Jung, Max, et al.
Publicado: (2023)

Pure Large Nested Variant of Urothelial Carcinoma (LNUC) Is the Prototype of an FGFR3 Mutated Aggressive Urothelial Carcinoma with Luminal-Papillary Phenotype
por: Weyerer, Veronika, et al.
Publicado: (2020)

Diagnostic and Prognostic Implications of FGFR3(high)/Ki67(high) Papillary Bladder Cancers
por: Geelvink, Mirja, et al.
Publicado: (2018)

The ECM Modulator ITIH5 Affects Cell Adhesion, Motility and Chemotherapeutic Response of Basal/Squamous-Like (BASQ) Bladder Cancer Cells
por: Rose, Michael, et al.
Publicado: (2021)

Identification and Validation of Potential New Biomarkers for Prostate Cancer Diagnosis and Prognosis Using 2D-DIGE and MS
por: Geisler, Cordelia, et al.
Publicado: (2015)

Heterogenous NECTIN4 expression in urothelial high-risk non-muscle-invasive bladder cancer
por: Garczyk, Stefan, et al.
Publicado: (2022)

Automated PD-L1 Scoring Using Artificial Intelligence in Head and Neck Squamous Cell Carcinoma
por: Puladi, Behrus, et al.
Publicado: (2021)

Pure high-grade papillary urothelial bladder cancer: a luminal-like subgroup with potential for targeted therapy
por: Schnitzler, Tician, et al.
Publicado: (2020)

Fibroblast growth factor receptor (FGFR) alterations in squamous differentiated bladder cancer: a putative therapeutic target for a small subgroup
por: Baldia, Philipp H., et al.
Publicado: (2016)

ITIH5 and ECRG4 DNA Methylation Biomarker Test (EI-BLA) for Urine-Based Non-Invasive Detection of Bladder Cancer
por: Rose, Michael, et al.
Publicado: (2020)

Editorial: Identifying novel biomarkers in bladder cancer
por: Ecke, Thorsten H., et al.
Publicado: (2023)

Promoter methylation of DNA damage repair (DDR) genes in human tumor entities: RBBP8/CtIP is almost exclusively methylated in bladder cancer
por: Mijnes, Jolein, et al.
Publicado: (2018)

Establishment and Characterization of an Empirical Biomarker SS/PV-ROC Plot Using Results of the UBC(®) Rapid Test in Bladder Cancer
por: Oehr, Peter, et al.
Publicado: (2020)

Illumination of a Vision 2020—Urinary Based Biomarkers for Bladder Cancer on the Way to Clinical Decisions—Dream or Nightmare?
por: Ecke, Thorsten H., et al.
Publicado: (2020)

Illumination of a Vision—How Arthur Rimbaud Will Give Us Motivation to Find New Input into Bladder Cancer Biomarker Research
por: Ecke, Thorsten H., et al.
Publicado: (2017)

Diagnostic and Prognostic Potential of MicroRNA Maturation Regulators Drosha, AGO1 and AGO2 in Urothelial Carcinomas of the Bladder
por: Rabien, Anja, et al.
Publicado: (2018)

The Prognostic Value of FGFR3 Expression in Patients with T1 Non-Muscle Invasive Bladder Cancer
por: Sikic, Danijel, et al.
Publicado: (2021)

High Androgen Receptor mRNA Expression Is Associated with Improved Outcome in Patients with High-Risk Non-Muscle-Invasive Bladder Cancer
por: Sikic, Danijel, et al.
Publicado: (2021)

Molecular Diagnostic and Prognostication Assays for the Subtyping of Urinary Bladder Cancer Are on the Way to Illuminating Our Vision
por: Ecke, Thorsten H., et al.
Publicado: (2022)

Cognitive function in patients undergoing cystectomy for bladder cancer – results from a prospective observational study
por: Grunewald, Camilla M., et al.
Publicado: (2022)

Predicting immune checkpoint inhibitor response in urothelial carcinoma: another step in personalised medicine?
por: Niegisch, Günter
Publicado: (2019)

Multicentric analytical comparability study of programmed death-ligand 1 expression on tumor-infiltrating immune cells and tumor cells in urothelial bladder cancer using four clinically developed immunohistochemistry assays
por: Schwamborn, Kristina, et al.
Publicado: (2019)

Detection of HHV-6 Virus in specimen of a ductal pancreatic adenocarcinoma with comparison in tumor and normal tissue
por: Warkentin, S., et al.
Publicado: (2023)

Many Different LINE-1 Retroelements Are Activated in Bladder Cancer
por: Whongsiri, Patcharawalai, et al.
Publicado: (2020)

TERT Promoter Mutation Analysis of Whole-Organ Mapping Bladder Cancers
por: Weyerer, Veronika, et al.
Publicado: (2021)

Prognostic impact of molecular muscle-invasive bladder cancer subtyping approaches and correlations with variant histology in a population-based mono-institutional cystectomy cohort
por: Weyerer, Veronika, et al.
Publicado: (2021)

Evaluating the Utility of Combined Bladder Cancer Biomarkers, the Molecular Prognostication of Tumor Subtypes, or What Else Is Needed to Illuminate Our Vision?
por: Ecke, Thorsten H., et al.
Publicado: (2020)

KRT20, KRT5, ESR1 and ERBB2 Expression Can Predict Pathologic Outcome in Patients Undergoing Neoadjuvant Chemotherapy and Radical Cystectomy for Muscle-Invasive Bladder Cancer
por: Jütte, Hendrik, et al.
Publicado: (2021)

Downregulation of Cell Cycle and Checkpoint Genes by Class I HDAC Inhibitors Limits Synergism with G2/M Checkpoint Inhibitor MK-1775 in Bladder Cancer Cells
por: Hoffmann, Michèle J., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_3hefvsqajs43dvrjfc04kmajia